^
Association details:
| Biomarker: | CDH1 expression |
|---|---|
| Cancer: | Pancreatic Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) + Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
Excerpt:
...we evaluated the safety and efficacy of selumetinib, a MEK1/2 inhibitor, plus erlotinib in patients with previously treated advanced PDAC....Patients with tumors exhibiting an epithelial phenotype (demonstrated by high level of E-cadherin expression) were more likely to be sensitive to study treatment.
DOI:
10.1158/1078-0432.CCR-15-0979
